Clinical evaluation for osteoporosis

Clinics in Geriatric Medicine

Volumn 19, Issue 2, 2003, Pages 299-320

  Becker, Carolyn ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN A; DIURETIC AGENT; FLUORIDE; GLUCOCORTICOID; GONADORELIN DERIVATIVE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; LOOP DIURETIC AGENT; METHOTREXATE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PHENOBARBITAL; PHENYTOIN; PROLACTIN; THYROID HORMONE; UNINDEXED DRUG; VITAMIN D;

AGED; AGING; ALCOHOLISM; BONE DENSITY; BONE MINERAL; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TURNOVER; CELIAC DISEASE; CIGARETTE SMOKING; CLINICAL EXAMINATION; CLINICAL TRIAL; COLLAGEN DISEASE; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CUSHING DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; ETHNIC GROUP; FAMILY HISTORY; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; GAUCHER DISEASE; HEMOCHROMATOSIS; HIP FRACTURE; HOMOCYSTINURIA; HUMAN; HYPERCALCIURIA; HYPOGONADISM; KIDNEY FAILURE; LABORATORY TEST; MALE; MALE OSTEOPOROSIS; MULTIPLE MYELOMA; OSTEOMALACIA; OSTEOPOROSIS; PHYSICAL EXAMINATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SYSTEMIC MASTOCYTOSIS; VITAMIN D DEFICIENCY;

BONE DENSITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MEDICAL HISTORY TAKING; OSTEOPOROSIS; PHYSICAL EXAMINATION; RISK FACTORS;

EID: 0037406814     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(02)00068-X     Document Type: Review

References (137)

1. Brown MA, Haughton MA, Grant SFA, et al. Genetic control of bone density and turnover: role of the collagen 1α1, estrogen receptor, and vitamin D receptor genes. J Bone Miner Res 2001;16: 758-64.
2. Johnson BE, Lucasey B, Tobinson RG, et al. Contributing diagnosis in osteoporosis. Arch Intern Med 1989;149:1069-72.
3. Kelepouris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Ann Intern Med 1995; 123:452-60.
4. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998;72:349-67.
5. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73.
6. Faulkner KG, McClung M, Cummings SR. Automated evaluation of hip axis length for predicting hip fracture. J Bone Miner Res 1994;9:1065-70.
7. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531-8.
8. Deng H.-W., Chen W.-M., Recker S, et al. Genetic determination of Colles' fracture and differential bone mass in women with and without Colles' fracture. J Bone Miner Res 2000; 15:1243-52.
9. Kotowicz MA, Melton JL, Cooper C, et al. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 1994;9:599-605.
10. Lauritzen JB, Schwarz P, McNair P, et al. Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. Osteoporos Int 1993;3: 133-7.
11. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
12. Melton III LJ, Atkinson EJ, Cooper C, et al. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999;10:214-21.
13. Ross PD, Davis JW, Epstein RS, et al. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
14. Kanis JA, Johnell O. The burden of osteoporosis. J Endocrinol Invest 1999;22:583-8.
15. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 1999;14:821-8.
16. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
17. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
18. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
19. Bonjour JP, Carrie AL, Ferrari S, et al. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 1997; 99:1287-94.
20. Maritini LA, Cuppari L, Colugnati FA, et al. High sodium chloride intake is associated with low bone density in calcium stone-forming patients. Clin Nephrol 2000;54:85-93.
21. Klein RF. Alcohol-induced bone disease: impact of ethanol on osteoblast proliferation. Alcohol Clin Exp Res 1997;21:392-9.
22. Peris P, Guanabens N, Pares A, et al. Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995;57:111-4.
23. Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med 1994;330:387-92.
24. Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. J Bone Miner Res 1991;6:331-8.
25. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997;315:841-6.
26. Ensrud KE, Cauley J, Lipschutz R, et al. Weight change and fractures in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1997;157:857-63.
27. Hui SL, Perkins AJ, Zhou L, et al. Bone loss at the femoral neck in premenopausal white women: effects of weight change and sex-hormone levels. J Clin Endocrinol Metab 2002;87: 1539-43.
28. Salamone LM, Cauley JA, et al. Effect of a lifestyle intervention on bone mineral density in premenopausal women: a randomized trial. Am J Clin Nutri 1999;70:97-103.
29. Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998;129:81-8.
30. Chapuy MC, Schott AM, Garnero P, et al. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. J Clin Endocrinol Metab 1996;81:1129-33.
31. Sambrook PN, Kelly PJ, Morrison NA, et al. Scientific review. Genetics of osteoporosis. Br J Rheumatol 1994;33:1007-11.
32. Riggs BL. Vitamin D-receptor genotypes and bone density. N Engl J Med 1997;337:125-6.
33. Uitterlinden AG, Burger H, Huang Q, et al. Relation of alleles of the collagen type 1α1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 1998;338:1016-21.
34. Nevitt MC. Epidemiology of osteoporosis. Osteoporosis 1994;20:535-54.
35. Siris E, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results form the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-22.
36. Faulkner KG, Cummings SR, Black D, et al. Simple measurement of femoral geometry predicts hip fracture; the Study of Osteoporotic Fractures. J Bone Miner Res 1993;8:1211-7.
37. Reed BY, Gitomer WL, Heller HJ, et al. Identifcation and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab 2002;87:1476-85.
38. Chandler JM, Zimmerman SI, Girman CJ, et al. Low bone mineral density and risk of hip fracture in white female nursing home residents. JAMA 2000;284:972-7.
39. National Institutes of Health. Osteoporosis prevention, diagnosis and therapy. NIH Consensus Statement 2000;17:1-45.
40. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. N Engl J Med 1995; 332:305-11.
41. Ross DS, Neer RM, Ridgway EC. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987;82:1167-70.
42. Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994;4:319-26.
43. Bauer DC, Ettinger B, Nevitt MC, et al. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001;134:561.
44. Hanna FW, Pettit RJ, Ammari F, et al. Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol (Oxford) 1998;48:229-34.
45. Pietschmann F, Breslau NA, Pak CY. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992;7:1383-8.
46. Lauderdale DS, Thisted RA, Wen M, et al. Bone mineral density and fracture among prevalent kidney stone cases in the third National Health and Nutrition Examination Survey. J Bone Miner Res 2001;16:1893-8.
47. Silverberg SJ, Shane E, Cruz LDL, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Metab 1989;4:283-91.
48. Wishart J, Horowitz M, Need M, et al. Relationship between forearm and vertebral mineral density in postmenopausal women with primary hyperparathyroidism. Arch Intern Med 1990; 150:1329-31.
49. Larsson K, Lindh E, Lind L, et al. Increased fracture risk in hypercalcemia: bone mineral content measured in primary hyperparathyroidism. Acta Orthop Scand 1989;60:268-70.
50. Larsson K, Ljunghall S, Krusemo B, et al. The risk of hip fractures in patients with primary hyperparathyroidism: a population based cohort study with a follow-up of 19 years. J Intern Med 1993;234:585-93.
51. Melton III LJ, Atkinson EJ, O'Fallon WM, et al. Risks of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med 1992;152:2269-73.
52. Wilson RJ, Rao DS, Ellis B, et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988;109:959-62.
53. Khosla S, Melton LJ, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999;14:1700-7.
54. Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991;49:155-60.
55. Kayath MJ, Dib SA, Vieiaa JG. Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabetes Complications 1994;8:97-104.
56. Tuominen JT, Impivaara O, Puukka P, et al. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999;22:1196-200.
57. Barrett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin dependent diabetes mellitus. JAMA 1992;268:3333-7.
58. Van Daele PLA, Stolk RP, Burger H, et al. Bone density in non-insulin dependent diabetes mellitus. Ann Intern Med 1995;122:409-14.
59. Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle aged Norwegian women and men. Am J Epidemiol 1993;137:1203-11.
60. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86:32-8.
61. Cundy TF, Edmunds ME, Watkins PJ. Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 1985;2:461-4.
62. Hermus AR, Smals AC, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995;80:2859-65.
63. Gloth FM, Gundberg CM, Hollis BW, et al. Vitamin D deficiency in homebound elderly persons. JAMA 1995;274:1683-6.
64. Lamberg-Allardt CJ, Outila TA, Karkkainen MU, et al. Vitamin D deficiency and bone health in healthy adults in Finland: could this be a concern in other parts of Europe? J Bone Miner Res 2001;16:2066-73.
65. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985;76:1536-8.
66. Harris SS, Soteriades E, Coolidge JA, et al. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab 2000;85:4125-30.
67. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777-83.
68. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal U.S. women with acute hip fracture. JAMA 1999;281:1505-11.
69. Minne HW, Pfeifer M, Begerow B, et al. Vitamin D and calcium supplementation reduces falls in elderly women via improvement of body sway and normalization of blood pressure: a prospective, randomized, and double-blind study. Osteoporos Int 2000;11 (Suppl 2):S115.
70. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15:1113-8.
71. Sambrook PN, Ansell BM, Foster S, et al. Bone turnover in early rheumatoid arthritis. 2. Longitudinal bone density studies. Ann Rheum Dis 1985;44:580-4.
72. McDougall R, Sibley J, Haga M, et al. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994;21:1207-13.
73. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross-sectional study of bone mineral density in rheumatoid arthritis. Arthritis Rheum 2000;43:2582-9.
74. Cooper C, Carbone L, Michet CJ, et al. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 1994;21:1877-81.
75. Will R, Palmer R, Bhalla AK, et al. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 1989;2:1483-5.
76. Spotila LD, Constantinou CD, Sereda L, et al. Mutation in a gene for type I procollagen (CO-L1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta. Proc Natl Acad Sci USA 1991;88:5423-7.
77. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.
78. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol 1998;103: 902-10.
79. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
80. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991;96:5S.
81. Church MK, Levi-Schaffer F. The human mast cell. J Allergy Clin Immunol 1997;99:155-60.
82. Floman Y, Amir G. Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures. J Spinal Disord 1991;4:369-73.
83. Rosenbaum RC, Frieri M, Metcalfe DD. Patterns of skeletal scintigraphy and their relationship to plasma and urinary histamine levels in systemic mastocytosis. J Nucl Med 1984;25:859-64.
84. McGovern MM, Desnick RJ. Lysosomal storage diseases. In: Goldman L, editor. Cecil textbook of medicine. 21st edition. Philadelphia: W.B. Saunders; 2000. p. 1105-6.
85. Selby PL, Davies M, Adams JE, et al. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999;14:652-7.
86. Kemppainen T, Kroger H, Janatuinen E, et al. Osteoporosis in adult patients with celiac disease. Bone 1999;24:249-55.
87. Mustalahti K, Collin P, Sievanen H, et al. Osteopenia in patients with clinically silent celiac disease warrant screening. Lancet 1999;28:744-5.
88. Shaker JL, Brickner RC, Findley JW, et al. Hypocalcemia and skeletal disease as presenting features of celiac disease. Arch Intern Med 1997;157:1013-6.
89. Lindh E, Ljunghall S, Larsson K, et al. Screening for antibodies against gliadin in patients with osteoporosis. J Intern Med 1992;231:403-6.
90. Nuti R, Martini G, Valenti R, et al. Prevalence of undiagnosed coeliac syndrome in osteoporotic women. J Intern Med 2001;250:361-6.
91. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995;108:276-83.
92. Rosen HN. Primary biliary cirrhosis and bone disease. Hepatology 1995;21:253.
93. Crippin J, Jorgenson R, Dickson R, et al. Hepatic osteodystrophy in primary biliary cirrhosis. Effects of medical treatment. Am J Gastroenterol 1994;89:47-50.
94. Hodgson SF, Dickson ER, Eastell R, et al. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993;14:819-27.
95. Guanabens N, Pares A, Marinoso L, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990;85:1356-62.
96. Janes CH, Dickson ER, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestafic jaundice. J Clin Invest 1995;95:2581-6.
97. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterol 1982;83:103-8.
98. Diamond T, Stiel D, Posen S. Osteoporosis in haemochromatosis: iron excess, gonadal deficiency or other factors? Ann Intern Med 1989;110:430-6.
99. Kelly TM, Edwards CQ, Meikle AW, et al. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984;101:629-32.
100. Eddy RL. Metabolic bone disease after gastrectomy. Am J Med 1971;50:442-9.
101. Mellstrom D, Johansson C, Johnell O, et al. Osteoporosis, metabolic aberrations and increased risk for vertebral fractures after partial gastrectomy. Calcif Tissue Int 1993;53:370-7.
102. Bernstein CN, Blanchard JF, Leslie W, et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000;133:795-9.
103. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-33.
104. Semeao EJ, Stallings VA, Peck SN, et al. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997;112:1710-3.
105. Silvennoinen JA, Karttunen TJ, Niemela SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71.
106. Cannata-Andia JB. Hypokinetic azotemic osteodystrophy. Kidney Int 1998;54:1000.
107. Cayco AV, Wysolmerski J, Simpson C, et al. Posttransplant bone disease: evidence for a high bone resorption state. Transplantation 2000;70:1722-8.
108. Julian BA, Benfield M, Quarles LD. Bone loss after organ transplantation. Transplant Rev 1993;7:82.
109. Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998;54:1704-13.
110. Lane NE, Lukert BP. The science and therapy of glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 1998;27:465-83.
111. Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-8.
112. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long term glucocorticoid therapy. Arch Int Med 1990;150:2545-8.
113. Van Staa TP. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39:1383-9.
114. Lems WF, Jahangier ZN, Jacobs JWG, et al. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 1995;13:293-7.
115. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991;18:804-8.
116. Lane NE. An update of glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 2001; 27:235-53.
117. Hahn TJ, Hendin BA, Scharp CR, et al. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972;287:900-4.
118. Nilsson OS, Lindholm TS, Elmstedt E, et al. Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment. Arch Orthop Trauma Surg 1986;105:146-9.
119. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment. J Clin Oncol 2000;18:1570-93.
120. Van Daele PL, Seibel MJ, Burger H, et al. Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam Study. BMJ 1996;312:482-3.
121. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998;13:297-302.
122. Chesnut 3rd CH, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type 1 collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.
123. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the Early Postmenopausal Intervention Cohort study. J Clin Endocrinol Metab 1999;84:2363-8.
124. Spitz J, Lauer I, Tittel K, et al. Scintimetric evaluation of remodeling after bone fractures in man. J Nucl Med 1993;34:1403-9.
125. Fogelman I, Carr D. A comparison of bone scanning and radiology in the evaluation of patients with metabolic bone disease. Clin Radiol 1980;31:321-6.
126. Looker AC, Orwoll ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997;12:1761-8.
127. Forsen L, Sogaard AJ, Meyer HE, et al. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999;10:73-8.
128. Hannan EL, Magaziner J, Wang JJ. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA 2001;285:2736-42.
129. Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med 1999;130:658-60.
130. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
131. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metabl 2001;86:5252-5.
132. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
133. Ringe JD, Dorst A, Kipshoven C, et al. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos Int 1998;8:47-52.
134. Erlacher L, Kettenbach J, Kiener H, et al. Salmon calcitonin and calcium in the treatment of male osteoporosis: the effect on bone mineral density. Wien Klin Wochenschr 1997;109:270-4.
135. Trovas GP, Lyritis GP, Galanos A, et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002;17:512-27.
136. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
137. Khosla S, Melton III JL, Riggs BL. Estrogen and the male skeleton. J Clin Endocrinol Metab 2002;87:1443-50.